↓ Skip to main content

Intermittent PTH administration improves alveolar bone formation in type 1 diabetic rats with periodontitis

Overview of attention for article published in Journal of Translational Medicine, March 2018
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
40 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Intermittent PTH administration improves alveolar bone formation in type 1 diabetic rats with periodontitis
Published in
Journal of Translational Medicine, March 2018
DOI 10.1186/s12967-018-1438-2
Pubmed ID
Authors

Ji-Hye Kim, Ae Ri Kim, Yun Hui Choi, Aeryun Kim, Yongsung Sohn, Gye-Hyeong Woo, Jeong-Heon Cha, Eun-Jung Bak, Yun-Jung Yoo

Abstract

Periodontitis is an infectious disease that manifests as alveolar bone loss surrounding the roots of teeth. Diabetes aggravates periodontitis-induced alveolar bone loss via suppression of bone formation. Intermittent parathyroid hormone (PTH) administration displays an anabolic effect on bone. In this study, we investigated the effect of intermittent PTH administration on alveolar bone loss in type 1 diabetic rats with periodontitis. Rats were divided into control (C), periodontitis (P), periodontitis treated with PTH (P + PTH), diabetes with periodontitis (DP), and diabetes with periodontitis treated with PTH (DP + PTH) groups. To induce type 1 diabetes, rats were injected with streptozotocin and periodontitis was induced bilaterally by applying ligatures to the mandibular first molars for 30 days. During the experimental period, the P + PTH and DP + PTH groups were subcutaneously injected with PTH (40 μg/kg) three times per week, whereas the C, P, and DP groups were injected with citrate buffer. To observe the mineralization of the alveolar bone, the DP and DP + PTH groups were injected with calcein on days 10 and 27, and with alizarin red on day 20. Thirty days after ligation, histological findings and fluorescence labeling were analyzed in the furcations of the mandibular first molars. Sclerostin-positive osteocytes were assessed by immunohistochemical analyses. The DP groups had smaller areas of alveolar bone than the other groups, and the DP + PTH group had a larger alveolar bone area than the DP group. The DP group had less osteoid formation than the C group, whereas the DP + PTH had greater osteoid formation than the DP group. Fluorescence labeling results revealed that the DP + PTH group had more mineral deposition on the alveolar bone than the DP group. The DP + PTH group exhibited lower percentage of sclerostin-positive osteocytes in alveolar bone than the DP group. Intermittent PTH administration diminishes alveolar bone loss and sclerostin expression in osteocytes, but increases osteoid formation and mineralization, suggesting that intermittent PTH administration attenuates diabetes-aggravated alveolar bone loss by the induction of bone formation. PTH-induced bone formation may be related to the regulation of osteocytic sclerostin expression in type 1 diabetic rats with periodontitis.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 40 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 5 13%
Student > Postgraduate 4 10%
Student > Master 4 10%
Student > Doctoral Student 3 8%
Other 3 8%
Other 9 23%
Unknown 12 30%
Readers by discipline Count As %
Medicine and Dentistry 18 45%
Biochemistry, Genetics and Molecular Biology 2 5%
Nursing and Health Professions 2 5%
Veterinary Science and Veterinary Medicine 1 3%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Other 2 5%
Unknown 14 35%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 March 2018.
All research outputs
#15,494,712
of 23,028,364 outputs
Outputs from Journal of Translational Medicine
#2,259
of 4,029 outputs
Outputs of similar age
#213,390
of 333,788 outputs
Outputs of similar age from Journal of Translational Medicine
#49
of 97 outputs
Altmetric has tracked 23,028,364 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,029 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one is in the 31st percentile – i.e., 31% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 333,788 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 97 others from the same source and published within six weeks on either side of this one. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.